Julie Grisham, MS

Memorial Sloan-Kettering physician-scientist Charles Sawyers, who serves as president of the American Association for Cancer Research, highlights findings from the group’s new report.

In this “Ask the Expert” feature, gynecologic surgeon Dennis Chi discusses why screening for ovarian cancer is not as widespread as it is for certain other cancers.

Information about the microbiome, the genes of all the microorganisms that naturally inhabit the human body, is leading to new approaches for treating infections in cancer patients.

Memorial Sloan-Kettering’s Brain Tumor Center provides world-class care to people with low-grade glioma, a type of slow-growing brain tumor.

Investigators have sequenced the genome of adenoid cystic carcinoma, a rare and deadly head and neck cancer. The work sets the stage for the sequencing of additional rare cancers at Memorial Sloan-Kettering.

Research suggests that a new drug could be effective in patients with prostate cancer who develop resistance to the targeted therapy enzalutamide.